Advantages of adding Metformin to Chemotherapy in Breast Cancer Patients

Efficacy of Combining Metformin with Neoadjuvant Chemotherapy on pathologic response in Non-Diabetic Patients with Carcinoma Breast â?? A randomized controlled trial

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012810

Enrollment

100

Registered

2018-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Carcinoma Breast

Interventions

Intervention1: Intervention- Metformin with Neoadjuvant Chemotherapy : Intervention-Study group will receive metformin along with neo adjuvant chemotherapy.Participants in Study group will be started

Eligibility

Inclusion criteria

Inclusion criteria: All non-diabetic Breast cancer women with BMI more than 22 planned for Neoadjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Patients with Renal disease, Hepatic disease, alcohol abuse, psychiatric disorder, pregnancy

Design outcomes

Primary

Measure	Time frame
To assess the effect of adding metformin to neo-adjuvant chemotherapy in Breast Cancer patientsTimepoint: 7 months after starting NACT	—

Secondary

Measure	Time frame
1. To establish safety and tolerance of metformin as a neo-adjuvant drug in Breast cancer. 2. To measure the effect of metformin on sex hormones. 3. To study the tumor response to Metformin using Ki67 level 4. To assess the effect of Metformin on insulin resistance Timepoint: 1) 1 week after last cycle of NACT 2) 7 months after start of NACT	—

Countries

India

Contacts

Public ContactNiraj Ghimire

Jawaharlal Institutre of Postgraduate Medical Education and Research

kadambari1909@gmail.com9843323420

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026